Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

13.7K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
13.7K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

211
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
211
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

149
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
149
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

189
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance and tumor cell interactions of tumor-associated neutrophils in gastric cancer.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Impact of Combined Frailty and Sarcopenia on Postoperative Outcomes and Survival in Elderly Gastric Cancer Patients Undergoing Gastrectomy.

Journal of gastric cancer·2026
Same author

Assessing Lymph Node Metastasis Risk in Patients With Mucosal Gastric Cancer: A Comparison of the WHO and Japanese Criteria and Implications for Endoscopic Submucosal Dissection.

JGH open : an open access journal of gastroenterology and hepatology·2026
Same author

Automated Assessment of Surgical Quality in Distal Gastrectomy: Development of a Novel Computer Vision Model Based on the Critical View of Quality (CVQ).

Annals of surgery·2026
Same author

Robotic-assisted gastrectomy for 700 gastric cancer patients: A comparative analysis between specialized centers in Italy and Korea.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

ASO Author Reflections: Need for a Textbook Outcome in Gastric Surgery (TOGS) Specific for Gastric Cancer.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Jan 6, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.2K

Metabolic Surgery for Obese Type 2 Diabetes: Korean Multicenter Cohort Study.

Young Suk Park1, Soo Min Ahn2, Sang Hyun Kim3

  • 1Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Seoul, Korea, Republic of.

Obesity Surgery
|November 13, 2025
PubMed
Summary

Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) show no significant difference in type 2 diabetes mellitus (T2DM) remission for Korean adults after 1-2 years. Further research is needed to confirm these findings.

Keywords:
Bariatric surgeryDiabetes mellitus, type 2Propensity scoreRoux-en-Y gastric bypassSleeve gastrectomy

More Related Videos

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

947
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.5K

Related Experiment Videos

Last Updated: Jan 6, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.2K
Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice
08:50

Duodenal-Jejunal Bypass Surgery in Diet-Induced Obese Diabetic Mice

Published on: October 18, 2024

947
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.5K

Area of Science:

  • Metabolic surgery
  • Bariatric procedures
  • Type 2 Diabetes Mellitus (T2DM) management

Background:

  • Metabolic/bariatric surgery effectively treats obesity and T2DM.
  • Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are common procedures.
  • Limited comparative data exists for East Asian populations.

Purpose of the Study:

  • To compare the metabolic benefits of SG and RYGB.
  • To assess T2DM remission rates in Korean adults.
  • To evaluate surgical outcomes at 1 and 2 years post-operation.

Main Methods:

  • Multicenter retrospective cohort study.
  • Korean adults (BMI ≥ 30 kg/m²) with T2DM undergoing SG or RYGB.
  • Primary outcome: complete T2DM remission at 1 and 2 years.
  • Inverse probability of treatment weighting (IPTW) for adjustment.

Main Results:

  • Unadjusted analysis favored SG for T2DM remission at 1 and 2 years.
  • Adjusted analysis (IPTW) showed no significant difference between SG and RYGB.
  • Shorter T2DM duration and no insulin use predicted remission, not surgical type.

Conclusions:

  • No statistically significant difference in T2DM remission between SG and RYGB in Korean patients.
  • Findings require cautious interpretation due to sample size and follow-up duration.
  • Prospective studies are necessary for clinical decision-making validation.